Epstein Barr Virus R Transactivator (RTA) Technology
A novel antibody enabling the detection and qualification of the RTA protein, a key factor in the detection of early Epstein Barr Virus.
Introduction
The R Transactivator (RTA) is one of the two main transactivators originating from the Epstein Barr Virus (EBV). It acts in synergy with the Zebra protein in the switch-latency productive cycle. The transactivator demonstrates significant potential as a marker for the early detection of EBV infection. This technology is available to license to organisations working in the field of monoclonal antibody distribution.
Features/Benefits
Monoclonal Antibody
Highly targeted
Validated for use in immunofluorescence/western blotting/Flow cytometry
Facilitates use in a research environment
UVHCI (Unit of Virus Host Cell Interactions), laboratory renowned at a European level
Specialists in the understanding of EBV biology
Applications
Detection of early Epstein Barr Virus infection
The technology has significant potential within a research environment
Scientific data
Name
Anti EBV R transactivator (Rta)
Clone
5A9 (IgG) // 8c12 (IgG) //4C1 (IgG)
Host species :
Mouse
Ig subclass :
Mouse monoclonal IgG
Culture medium
RPMI 1640 with FCS GIBCO (Invitrogene) 10%
References :
Imbert-Marcille et al. Clin. Diagn. Lab Immunol. 7 : 206-211.2000 Feederle R. et al. EMBO J. 19 : 3080-3089.2000
Commercial Opportunities
This technology is available to license to organisations working in the field of monoclonal antibody distribution.
Contact Technology Transfer Manager Pascale Grenard-Ecuyer +33 476 00 78 34
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
